Caribou Biosciences vs Relay Therapeutics
CRBU and RLAY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRBU and RLAY compare
Relay Therapeutics is the larger company, worth 102 times as much as Caribou Biosciences ($4.0B against $38.8M).
Relay Therapeutics grew revenue faster over the last twelve months (23.9% versus 1.6% for Caribou Biosciences).
Caribou Biosciences keeps more of each dollar of sales as profit, with a net margin of −1085% compared with −2837% at Relay Therapeutics.
Relay Therapeutics scores higher on the StockData Score (10 against 8 for Caribou Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRBU | RLAY |
|---|---|---|
| Size and price | ||
| Market cap | $38.8M | $4.0B |
| Share price | $0.362 | $18.09 |
| Change, 1 year | −84.0% | 193% |
| Change, 5 years | −98.3% | −47.5% |
| Beta (5Y) | 1.94 | 1.94 |
| Employees | 97 | 192 |
| StockData Score | ||
| Total score | 8 | 10 (better) |
| Valuation score | 3 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.1× (better) | 383× |
| P/B | 0.5× (better) | 4.8× |
| FCF yield | −240% | – |
| Fair value | $1.08 | – |
| Margin of safety | 66.4% | – |
| Growth | ||
| Revenue growth (TTM) | 1.6% | 23.9% (better) |
| Revenue growth, 5Y average | −2.0% (better) | −28.6% |
| Profitability | ||
| Operating margin | −1141% (better) | −3095% |
| Net margin | −1085% (better) | −2837% |
| FCF margin | −985% | – |
| Return on equity | −93.8% | −41.2% (better) |
| Return on invested capital | – | −41.8% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.97 | 14.62 (better) |
| Altman Z-score | −9.18 | 25.18 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | −69.3% | – |
| Shareholder yield | −69.3% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 45.5% | 113% |
| Held by insiders | 5.7% | 24.5% |
| Insider net buying, 12 months | −$47.5K (better) | −$129M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 14.7% | 26.4% |
Go deeper
- CRBU stock overview
- CRBU income statement
- CRBU valuation and score
- RLAY stock overview
- RLAY income statement
- RLAY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.